Reviewer's report

Title: Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.

Authors:

Dr Salvatore Gulli (salvatoregulli2@virgilio.it)
Carlo Arrigo (carrigo@inwind.it)
Loredana Bocchino (lobo73@inwind.it)
Lucia Morgante (luciamorgante@libero.it)
Donatella Sangari (donatella.sangari@tiscali.it)
Irene Castagna (castagna@unime.it)
Gianfilippo Bagnato (bagnato@unime.it)

Version: 2 Date: 15 Apr 2003

Reviewer: guidog Valesini

Level of interest: A paper of limited interest

Advice on publication: Reject

Comment

This is a case report on the efficacy of Infliximab in Behcet's disease. Several similar reports are now published in literature, most of them not reported nor discussed by the authors. The authors should add to the description of the case a wider discussion taking into account the more recent case series and single reports on the topic (Travis, 2001; Rozembaum, 2002; Triolo, 2002; Kram , 2003), in particular the efficacy of Infliximab after the failure of Embrel could be reported (Estrach, 2002). A table with a summary of all the cases described may be useful (age of the patient, dose of Infliximab and length of administration, kind of clinical involvement, side effects, etc etc).

Even if it'd be beyond the scope of this brief report, the role of TNF-alfa in the pathogenesis of Behcet's disease should be discussed more properly.

The case history is rather brief and some data are missing: only the name of the drugs taken before Infliximab are given while no information is available about their dosage and time of administration. Were any other drug(s) administered concomitantly to Infliximab? The description of eye involvement is poor: how and with which schedule of time was the eye examined? Images documenting eye improvement should be added if possible.

The authors conclude about the lack of infections during therapy: did they perform PPD Mantoux before infusion?

Page 4, first line: orogenital ulcerations

Competing interests:

None declared.